A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy

Marcus, 2014, Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer, Expert Opin Biol Ther, 14, 947, 10.1517/14712598.2014.900540

Torikai, 2012, A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR, Blood, 119, 5697, 10.1182/blood-2012-01-405365

Marcus, 2011, Redirected tumor-specific allogeneic T cells for universal treatment of cancer, Blood, 118, 975, 10.1182/blood-2011-02-334284

Berdien, 2014, TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer, Gene Ther, 21, 539, 10.1038/gt.2014.26

Benichou, 2011, Immune recognition and rejection of allogeneic skin grafts, Immunotherapy, 3, 757, 10.2217/imt.11.2

Jordheim, 2013, Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases, Nat Rev Drug Discov, 12, 447, 10.1038/nrd4010

Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol, 33, 540, 10.1200/JCO.2014.56.2025

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134

Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388

Galetto, 2014, Pre-TCRα supports CD3-dependent reactivation and expansion of TCRα-deficient primary human T-cells, Mol Ther Methods Clin Dev, 1, 14021, 10.1038/mtm.2014.21

Kim, 2013, TALENs and ZFNs are associated with different mutation signatures, Nat Methods, 10, 185, 10.1038/nmeth.2364

Juillerat, 2014, Comprehensive analysis of the specificity of transcription activator-like effector nucleases, Nucleic Acids Res, 42, 5390, 10.1093/nar/gku155

Guilinger, 2014, Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity, Nat Methods, 11, 429, 10.1038/nmeth.2845

Philip, 2014, A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy, Blood, 124, 1277, 10.1182/blood-2014-01-545020

Gandhi, 2003, Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias, Clin Cancer Res, 9, 6335

Long-Boyle, 2011, High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation, Bone Marrow Transplant, 46, 20, 10.1038/bmt.2010.53

Avramis, 1990, Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients, Cancer Res, 50, 7226

Zhao, 2010, Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor, Cancer Res, 70, 9053, 10.1158/0008-5472.CAN-10-2880

Bagley, 2009, Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs, Int J Oncol, 34, 1329

Waud, 2000, Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine (Cl-F-ara-A), Nucleosides Nucleotides Nucleic Acids, 19, 447, 10.1080/15257770008033020

Takahashi, 1999, Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration, Cancer Chemother Pharmacol, 43, 233, 10.1007/s002800050889

Valdez, 2012, Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines, Leuk Lymphoma, 53, 973, 10.3109/10428194.2011.634043

Valton, 2014, Efficient strategies for TALEN-mediated genome editing in mammalian cell lines, Methods, 69, 151, 10.1016/j.ymeth.2014.06.013

Piganeau, 2013, Cancer translocations in human cells induced by zinc finger and TALE nucleases, Genome Res, 23, 1182, 10.1101/gr.147314.112

Ghezraoui, 2014, Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining, Mol Cell, 55, 829, 10.1016/j.molcel.2014.08.002

Reichard, 1988, Interactions between deoxyribonucleotide and DNA synthesis, Annu Rev Biochem, 57, 349, 10.1146/annurev.bi.57.070188.002025

Wallen, 2009, Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma, PLoS One, 4, e4749, 10.1371/journal.pone.0004749

Gattinoni, 2005, Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells, J Exp Med, 202, 907, 10.1084/jem.20050732

Choudhary, 2013, Knockdown of HPRT for selection of genetically modified human hematopoietic progenitor cells, PLoS One, 8, e59594, 10.1371/journal.pone.0059594

Gori, 2010, In vivo selection of human embryonic stem cell-derived cells expressing methotrexate-resistant dihydrofolate reductase, Gene Ther, 17, 238, 10.1038/gt.2009.131

Porter, 2008, Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection, Blood, 112, 4466, 10.1182/blood-2008-03-146571

Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514

Dudley, 2005, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma, J Clin Oncol, 23, 2346, 10.1200/JCO.2005.00.240

Nars, 2013, Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy, Int J Cancer, 132, 2471, 10.1002/ijc.27801

Takebe, 2001, Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene, Mol Ther, 3, 88, 10.1006/mthe.2000.0236

Dasgupta, 2012, Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy, Hum Gene Ther, 23, 711, 10.1089/hum.2011.172

Jonnalagadda, 2013, Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy, PLoS One, 8, e65519, 10.1371/journal.pone.0065519

Huye, 2011, Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination, Mol Ther, 19, 2239, 10.1038/mt.2011.179

Beyer, 2005, Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine, Blood, 106, 2018, 10.1182/blood-2005-02-0642

Gabrilovich, 2012, Coordinated regulation of myeloid cells by tumours, Nat Rev Immunol, 12, 253, 10.1038/nri3175

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842

Colovos, 2012, Safety and stability of retrovirally transduced chimeric antigen receptor T cells, Immunotherapy, 4, 899, 10.2217/imt.12.91

Scholler, 2012, Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells, Sci Transl Med, 4, 132ra53, 10.1126/scitranslmed.3003761

Di Stasi, 2011, Inducible apoptosis as a safety switch for adoptive cell therapy, N Engl J Med, 365, 1673, 10.1056/NEJMoa1106152

Williams, 2007, T cell immune reconstitution following lymphodepletion, Semin Immunol, 19, 318, 10.1016/j.smim.2007.10.004

Daboussi, 2014, Genome engineering empowers the diatom Phaeodactylum tricornutum for biotechnology, Nat Commun, 5, 3831, 10.1038/ncomms4831